2019
Short-term Outcomes of Transanal Hemorrhoidal Dearterialization With Mucopexy Versus Vessel- Sealing Device Hemorrhoidectomy for Grade III to IV Hemorrhoids: A Prospective Randomized Multicenter Trial
Trenti L., Biondo S., Moreno E. K., et al. Diseases of the Colon & Rectum: August 2019 - Volume 62 – Issue 8 - p 988-996
BACKGROUND
Transanal hemorrhoidal dearterialization with mucopexy and vessel-sealing device hemorrhoidectomy seem to reduce postoperative pain compared with classic excisional hemorrhoidectomy, but whether one of them is superior remains unclear.
OBJECTIVE
We compared transanal hemorrhoidal dearterialization with mucopexy and vessel-sealing device hemorrhoidectomy.
DESIGN
This was a multicenter, randomized controlled trial.
SETTING
The study was conducted at 6 Spanish centers.
PATIENTS
Patients aged ≥18 years with grade III to IV hemorrhoids were included.
INTERVENTIONS
Patients were randomly assigned to transanal hemorrhoidal dearterialization with mucopexy (n = 39) or vessel-sealing device hemorrhoidectomy (n = 41).
MAIN OUTCOME MEASURES
Primary outcome was the mean postoperative number of days in which patients needed nonsteroidal antiinflammatory drugs. Secondary outcomes were postoperative pain, 30-day morbidity, patient satisfaction, Vaizey score, hemorrhoid symptoms score, return to work, and quality of life.
RESULTS
More patients were still taking analgesia in the vessel-sealing device hemorrhoidectomy group during the second postoperative week compared with the transanal hemorrhoidal dearterialization with mucopexy group (87.8% vs 53.8%; p = 0.002). For the transanal hemorrhoidal dearterialization with mucopexy group, analgesia consumption continued until day 10.1 (mean; SD = 7.22 d), whereas in the vessel-sealing device hemorrhoidectomy group it continued until day 15.2 (mean; SD = 8.70 d; p = 0.006). The mean daily average pain was similar during the first (p = 0.900) and second postoperative weeks (p = 0.265). Mean operative time was higher for the transanal hemorrhoidal dearterialization with mucopexy group versus the vessel-sealing device hemorrhoidectomy group (45 min; range, 40-60 vs 20 min; range, 15-41 min; p < 0.001). Postoperative complications rate, use of laxatives, patient satisfaction, Vaizey score, hemorrhoids symptoms score, return to work, and quality of life at 1 month after surgery were similar between groups.
LIMITATIONS
The main limitation of this study was that the 2 groups did not contain equal numbers of grade III and IV hemorrhoids.
CONCLUSIONS
Transanal hemorrhoidal dearterialization with mucopexy is associated with a shorter need for postoperative analgesia compared with vessel-sealing device hemorrhoidectomy. See Video Abstract at http://links.lww. com/DCR/A915.
TRIAL REGISTRATION
Clinicaltrials.gov identifier: NCT02654249.
Indietro